---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-024680"
form_type: "8-K"
ticker: "LIXT"
cik: "0001335105"
company_name: "LIXTE BIOTECHNOLOGY HOLDINGS, INC."
filed_at: "2025-08-19T23:59:59+00:00"
generated_at: "2026-05-17T11:22:51.663897+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# LIXTE raises $6.5M, adds new CEO/board members, regains Nasdaq compliance

## Summary
- Completed two financings raising $6.5M gross ($5M private placement + $1.5M registered direct); proceeds for working capital.
- Regained compliance for continued listing on Nasdaq Capital Market.
- Geordan Pursglove appointed Chairman and CEO in June 2025; Bas van der Baan becomes President and CSO.
- Nature published findings validating LB-100 mechanism; new pre-clinical study with Netherlands Cancer Institute.
- Jason Sawyer and Michael Holloway joined Board as independent directors; Forman and Yen moved to Scientific Advisory Committee.

## SEC filing metadata
- accession: 0001641172-25-024680
- form_type: 8-K
- ticker: LIXT
- cik: 0001335105
- company_name: LIXTE BIOTECHNOLOGY HOLDINGS, INC.
- filed_at: 2025-08-19T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1335105/000164117225024680/0001641172-25-024680-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1335105/000164117225024680/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-024680
- JSON: https://secwatch.observer/filing/0001641172-25-024680.json
- Plain text: https://secwatch.observer/filing/0001641172-25-024680.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.